Regulatory Update on Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA Announced September 9, 2025
Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
Final Topline Survival Data from VERSATILE-002 Ph 2 Trial in 1L R/M HNSCC showing median OS of 39.3 months in patients with CPS ≥ 1 announced August 26, 2025
Positive Feedback Received from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 August 11, 2025
LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy August 5, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as 1L Treatment for Nasopharyngeal Carcinoma July 15, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
Early-Stage Clinical Data and Anti-Proliferative Results Reported for APR-1051 in HPV+ HNSCC July 1, 2025
FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced SCCHN as Neoadjuvant and Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent June 17, 2025
FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints April 30, 2025
Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated March 18, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for HNSCC March 18, 2025
Head and Neck Cancer Registration Study Protocol Clears FDA Review; in Talks with Potential Partners Interested in Commercialization of Multikine March 18, 2025
JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression March 18, 2025
VERSATILE-003 Ph 3 Trial of Versamune HPV in HPV16-Positive Head and Neck Cancer Initiated March 11, 2025
Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations March 11, 2025
